<DOC>
	<DOCNO>NCT02698215</DOCNO>
	<brief_summary>This study double-blind , randomize clinical trial use two group medication design consist combination VAR ( 1 mg twice daily ) + NTX ( 50 mg daily ) VAR ( 1 mg twice daily ) + PLA ( match NTX ) , smoke cessation sample heavy drinking daily smoker want quit smoking reduce drinking .</brief_summary>
	<brief_title>Combining Varenicline Naltrexone Smoking Cessation</brief_title>
	<detailed_description>This study double-blind , randomize clinical trial use two group medication design consist combination VAR ( 1 mg twice daily ) + NTX ( 50 mg daily ) VAR ( 1 mg twice daily ) + PLA ( match NTX ) , smoke cessation sample heavy drinking daily smoker want quit smoking reduce drinking . All participant daily smoker ( ≥ 5 cig/day ) also heavy drinker accord National Institute Alcohol Abuse Alcoholism ( NIAAA ) guideline : men , &gt; 14 drink per week ≥ 5 drink per occasion least per month past 12 month ; woman , &gt; 7 drink per week ≥ 4 drink per occasion least per month past 12 month . A total 274 participant randomize , 137 medication group .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Be treatmentseeking smoke cessation desire reduce quit drink 2 . Be age 21 65 3 . Be able provide inform consent 4 . Smoke 5 cigarette per day past year 5 . Currently drink heavily accord National Institute Alcohol Abuse Alcoholism ( NIAAA ) guideline : men , &gt; 14 drink per week ≥ 5 drink per occasion least per month past 12 month ; woman , &gt; 7 drink per week ≥ 4 drink per occasion least per month past 12 month 6 . Pass physical exam associate laboratory test , determine study physician 1 . Have clinically significant alcohol withdrawal , indicate score ≥ 10 Clinical Institute Withdrawal Assessment Alcohol ( CIWAAr ) assess inperson screen visit 2 . Have lifetime DSMV diagnosis schizophrenia , bipolar disorder , psychotic disorder , psychiatric disorder determine clinical interview 3 . Have major depressive disorder within past year require treatment determine clinical interview use DSMV criterion 4 . Have current lifetime DSMV diagnosis substance use disorder , alcohol nicotine , determine clinical interview 5 . Have prior history take FDA approve medication ( i.e . varenicline bupropion ) smoke cessation 6 . Be currently use form nicotine replacement therapy ( past use acceptable ) 7 . Be currently use tobacco product cigarette ( ecigarettes , cigar , chew tobacco ) 8 . Have serious medical illness ( significant cardiovascular disease ; uncontrolled hypertension ; hepatic renal disease ) would contraindicate participation , determine study physician 9 . Be currently take insulin oral hypoglycemic medication 10 . Be currently take opioid pain medication form opioid agonist maintenance therapy ( methadone buprenorphine ) 11 . Be currently take psychoactive medication ; antidepressant , mood stabilizer , antiseizure medication , sedativeshypnotics , anxiolytic , stimulant antipsychotics 12 . Have selfreported use cocaine , methamphetamine , heroin illicit drug previous 60 day , verified urine toxicology screen 13 . For woman , must pregnant ( indicated selfreport positive pregnancy test study visit ) , nursing , plan become pregnant take part study , must agree reliable method birth control</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>